FindTrial
Sign In

The dosimetry study of 68Ga-EB-TATE on healthy volunteers and the comparison study of 68Ga-EB-TATE and 68Ga-NOC on neuroendocrine tumor patients

The dosimetry study of 68Ga-EB-TATE on healthy volunteers and the comparison study of 68Ga-EB-TATE and 68Ga-NOC on neuroendocrine tumor patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPh-16010101
Enrollment
Unknown
Registered
2016-12-07
Start date
2016-12-06
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuroendocrine tumor

Interventions

Healthy volunteers:68Ga-EB-TATE
The dosimetry study of 68Ga-EB-TATE on healthy volunteers and the comparison study of 68Ga-EB-TATE and 68Ga-NOC on neuroendocrine tumor patients:68Ga-EB-TATE + 68Ga-NOC

Sponsors

Xijing Hospital, Fourth Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Highly suspected neuroendocrine tumor; 2. The pathological findings are available; 3. Not receive radiotherapy or chemotherapy; 4. Generally in good condition, good liver/renal function.

Exclusion criteria

Exclusion criteria: 1. The pathological findings are unavailable; 2. Pregnancy

Design outcomes

Primary

MeasureTime frame
SUV;—

Countries

China

Contacts

Public ContactWang Jing

Xijing Hospital, Fourth Military Medical University

wangjing@fmmu.edu.cn+86 029 84775453

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026